We showed that 17β-estradiol (E 2) favors pancreatic β-cell survival via the estrogen receptor-α (ERα) in mice. E 2 activates nuclear estrogen receptors via an estrogen response element (ERE). E 2 also activates nongenomic signals via an extranuclear form of ERα and the G protein–coupled estrogen receptor (GPER). We studied the contribution of estrogen receptors to islet survival.
We used mice and islets deficient in estrogen receptor-α (αERKO −/−), estrogen receptor-β (βERKO −/−), estrogen receptor-α and estrogen receptor-β (αβERKO −/−), and GPER (GPERKO −/−); a mouse lacking ERα binding to the ERE; and human islets. These mice and islets were studied in combination with receptor-specific pharmacological probes.
We show that ERα protection of islet survival is ERE independent and that E 2 favors islet survival through extranuclear and membrane estrogen receptor signaling. We show that ERβ plays a minor cytoprotective role compared to ERα. Accordingly, βERKO −/− mice are mildly predisposed to streptozotocin-induced islet apoptosis. However, combined elimination of ERα and ERβ in mice does not synergize to provoke islet apoptosis. In αβERKO −/− mice and their islets, E 2 partially prevents apoptosis suggesting that an alternative pathway compensates for ERα/ERβ deficiency. We find that E 2 protection of islet survival is reproduced by a membrane-impermeant E 2 formulation and a selective GPER agonist. Accordingly, GPERKO −/− mice are susceptible to streptozotocin-induced insulin deficiency.